Hosted on MSN1d
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.
biopharma-reporter23d
Teva and Sanofi’s IBD drug hits Phase 2 targets
Teva announced it was partnering with Sanofi to further develop duvakitug for treatment of IBD in October last year. The drug was developed by the Israeli big pharma to target TL1A (TNF superfamily ...
IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development
Shares of IBD 50's GeneDx surged Monday after the Food and Drug Administration issued guidance about using AI to develop ...
verywellhealth1mon
Getting a Flu Shot While Taking Immunosuppressants
This is thought to keep the inflammation from IBD in check. However, this also means that the body is less able to fight off infections, such as those that are caused by bacteria or viruses, including ...
IBD 50's GeneDx Adds To Nearly 2,700% Sprint With FDA Guide On AI
Shares of the IBD 50's GeneDx surged Monday after the Food and Drug Administration issued guidance about using AI to develop ...
WebMD29d
Inflammatory Bowel Disease: Symptoms and Treatment
It also may be used when a child with IBD isn't growing well. If you don't respond to the drugs and other treatments recommended for IBD, talk with your doctor about enrolling in a clinical trial.
GlobalData on MSN1d
Insilico announces positive results from Phase I trials of AI-designed ISM5411
ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.
Le Lézard1d
Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access to complex medicines, today announced the expansion of its collaboration with Parvus ...